Neuphoria Therapeutics Inc. (NEUP) Stock Analysis & Investment Frameworks

Neuphoria Therapeutics Inc. (NEUP) stock analysis on Invetso. Review Neuphoria Therapeutics Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Neuphoria Therapeutics Inc. Company Overview

Neuphoria Therapeutics Inc. Key Financial Metrics

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.

Neuphoria Therapeutics Inc. Investment Frameworks

Invetso analyzes Neuphoria Therapeutics Inc. (NEUP) across the following frameworks:

Explore More NEUP Research